DUBLIN, Calif., March 1 /PRNewswire-FirstCall/ -- SuperGen Inc. today announced that it will Webcast its Analyst and Investor Day presentations beginning noon EST on Friday, March 2, 2007, from Salt Lake City, Utah. The presentations will include corporate and scientific updates with specifics on several drug discovery programs.
One update will focus on MP470, SuperGen’s multi-targeted tyrosine kinase inhibitor, and its suppression of RAD51 expression. This interaction will be the subject of an upcoming poster presentation at the American Association for Cancer Research annual meeting April 14-18 in Los Angeles.
The company will also review its progress with the JAK2 tyrosine kinase inhibitor program. This program exemplifies the efficiency and productivity of SuperGen’s drug discovery platform through an accelerated timeline from concept to pre-clinical candidate development in only nine months.
In addition, SuperGen will provide a detailed presentation of its CLIMB(TM) technology platform, which enables the company to discover and advance drug candidates rapidly while minimizing the financial risk inherent in traditional discovery efforts.
The presentations will be Webcast by CCBN and can be accessed in the Investor Relations section of SuperGen’s Web site at www.supergen.com. A replay will be available in the same location for 90 days following the event.
About SuperGen
Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company’s results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company’s filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts: SuperGen Timothy L. Enns S.V.P., Corporate Communications & Business Development (925) 560-0100 x111 tenns@supergen.com Noonan Russo Greg Geissman Director of Media Relations (858) 646-3058 greg.geissman@eurorscg.com
SuperGen Inc.
CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment of SuperGen, +1-925-560-0100 x111, tenns@supergen.com; or GregGeissman, Director of Media Relations, Noonan Russo, +1-858-646-3058,greg.geissman@eurorscg.com
Web site: http://www.supergen.com/
